Want to see HK:3681 full AI Analyst Report?
SinoMab Bioscience Ltd. (3681) Stock Statistics & Valuation Metrics
Total Valuation
SinoMab Bioscience Ltd. has a market cap or net worth of HKD 1.47B. The enterprise value is HKD 1.43B.
- Market Cap
- HKD 1.47B
- Enterprise Value
- HKD 1.43B
Share Statistics
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,386,638,300
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
SinoMab Bioscience Ltd.’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -14.73%.
- Return on Equity (ROE)
- -0.20
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- -14.73%
- Return on Capital Employed (ROCE)
- -0.18
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.40M
- Employee Count
- 73
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of SinoMab Bioscience Ltd. is -6.84. SinoMab Bioscience Ltd.’s PEG ratio is 0.19.
- PE Ratio
- -6.84
- PS Ratio
- 0.00
- PB Ratio
- 3.44
- Price to FCF
- -11.10
- Price to Operating Cash Flow
- -15.48
- PEG Ratio
- 0.19
Income Statement
In the last 12 months, SinoMab Bioscience Ltd. had revenue of 0 and earned -102.27M in profits. Earnings per share was -0.08.
- Revenue
- 0
- Gross Profit
- -26.64M
- Operating Income
- -124.70M
- Pretax Income
- -102.27M
- Net Income
- -102.27M
- EBITDA
- -72.11M
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was -80.23M and capital expenditures -32.56M, giving a free cash flow of -112.79M billion.
- Operating Cash Flow
- -80.23M
- Free Cash Flow
- -112.79M
- Free Cash Flow per Share
- -0.08
Dividends & Yields
SinoMab Bioscience Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.01%
- Earnings Yield
- -14.63%
Stock Price Statistics
- Beta
- 1.00
- 52-Week Price Change
- -32.66%
- 50-Day Moving Average
- 1.08
- 200-Day Moving Average
- 1.37
- Relative Strength Index (RSI)
- 48.97
- Average Volume (3m)
- 756.43K
Important Dates
SinoMab Bioscience Ltd. upcoming earnings date is Mar 22, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Mar 22, 2027
- Ex-Dividend Date
- ―
Financial Position
SinoMab Bioscience Ltd. as a current ratio of 1.91, with Debt / Equity ratio of 66.65%
- Current Ratio
- 1.91
- Quick Ratio
- 1.91
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- -0.07
- Interest Coverage Ratio
- -23.16
Taxes
In the past 12 months, SinoMab Bioscience Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
SinoMab Bioscience Ltd. EV to EBITDA ratio is -10.69, with an EV/FCF ratio of -11.92.
- EV to Sales
- 0.00
- EV to EBITDA
- -10.69
- EV to Free Cash Flow
- -11.92
- EV to Operating Cash Flow
- -16.76
Balance Sheet
SinoMab Bioscience Ltd. has HKD 226.21M in cash and marketable securities with HKD 266.78M in debt, giving a net cash position of -HKD 40.57M billion.
- Cash & Marketable Securities
- HKD 226.21M
- Total Debt
- HKD 266.78M
- Net Cash
- -HKD 40.57M
- Net Cash Per Share
- -HKD 0.03
- Tangible Book Value Per Share
- HKD 0.26
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for SinoMab Bioscience Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -4.24%
Scores
- Smart Score
- 3
- AI Score
- 43